News
No events scheduled at this time.
April 8, 2025
Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia
January 30, 2025
Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia
January 17, 2024
Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia
August 28, 2023
Comanche Biopharma Named by Fierce Biotech as a “Fierce 15” Biotech Company of 2023
August 23, 2023
Comanche Biopharma Receives US FDA Fast Track Designation for CBP-4888 for the Treatment of sFlt-1 mediated pre-term preeclampsia
June 13, 2023
Comanche Biopharma Strengthens Board of Directors with Appointment of Dr. Ann Taylor
March 30, 2023
Comanche Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for CBP-4888, an siRNA Investigational Therapy for the Treatment of Preeclampsia
December 15, 2022
Comanche Biopharma Announces Appointment of Allison August, M.D., as Chief Medical Officer
Media Contact
Liz Melone
Melone Communications, LLC
Mobile: +1 617-256-6622
Email: press@comanchebiopharma.com
Learn More
Contact Us
50 Beharrell St, Unit B
Concord, MA 01742